AXGN — AxoGen, Inc.

Summary of AXGN Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $59.9 million, a 21.3% increase year-over-year.
• Full Year Revenue: $225.2 million, up 20.2% compared to 2024.
• Adjusted EBITDA: Q4 adjusted EBITDA was $6.5 million; full year adjusted EBITDA increased 41% to $27.9 million.
• Net Loss: Q4 net loss was $13.2 million ($0.28 per share), compared to a net income of $500,000 in Q4 2024. Full year net loss was $15.7 million ($0.34 per share), worsening from a loss of $10 million in 2024.
• Gross Margin: Q4 gross margin was 74.1%, down from 76.1% in Q4 2024. Full year gross margin was 74.3%, slightly lower than 75.8% in 2024.
• Operating Expenses: Increased to $54.2 million in Q4, up from $35.6 million in Q4 2024.

2. Strategic Updates and Business Highlights

• Market Growth: Achieved double-digit growth across all target markets, with Avance Nerve Graft as the primary growth driver.
• FDA Approval: Received FDA approval for Avance as the first biologic therapeutic for peripheral nerve repair, expected to enhance market position and reimbursement opportunities.
• Sales Force Expansion: Increased sales representatives across all markets, with plans to continue this growth into 2026.
• High-Potential Accounts: 61% of revenue growth came from high-potential accounts, with a goal to maintain this momentum in 2026.
• Training Initiatives: Exceeded surgeon training targets in 2025 and plan to expand educational programs in 2026.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected to be at least 18%, targeting total revenue of at least $265.7 million.
• Gross Margin Guidance: Anticipated to remain between 74% to 76% in 2026, with improvements expected in 2027.
• Free Cash Flow: Expected to be positive for the full year 2026, despite higher cash burn anticipated in Q1.

4. Bad News, Challenges, or Points of Concern

• Net Loss: The company reported a significant net loss in Q4 and for the full year, indicating ongoing financial challenges.
• Gross Margin Decline: Margins decreased year-over-year, impacted by higher product costs associated with the transition to biologics.
• Sales and Marketing Expenses: Increased as a percentage of revenue, raising concerns about cost management.
• Market Risks: The transition to outpatient settings and reimbursement changes are uncertain and may affect future revenue streams.

5. Notable Q&A Insights

• Guidance Prudence: Management characterized the 18% revenue growth guidance as conservative, emphasizing the need for careful management of customer creation processes.
• Payer Engagement: The FDA approval allows for renewed discussions with payers, but no specific timelines for coverage decisions were provided.
• Sales Force Strategy: The company plans to incrementally grow its sales force to ensure adequate market coverage, particularly in extremities and breast markets.
• Clinical Evidence Requirements: Future clinical studies will vary by indication, with randomized trials required for some areas, while others may rely on controlled studies.

Overall, Axogen demonstrated strong growth in 2025, marked by significant strategic achievements and a focus on expanding its market presence, despite facing challenges related to profitability and margin pressures.